Blockade of TIGIT-PVR Axis can Treat Breast Cancer
Keywords:TIGIT, Checkpoint Inhibitor, Cancer, Breast, PVR, immunology
This review covers the identification and application of anti-TIGIT antibodies as checkpoint inhibitors for the treatment of triple-negative breast cancers. The original article, Targeting the TIGIT-PVR Immune Checkpoint Axis as Novel Therapeutic Option in Breast Cancer, was published by Stamm et al. in Oncoimmunology in October of 2019.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.